Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06920004 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
A Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP, sponsored by argenx.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 218
- Enrollment target
- 20
- Study locations
NCT06920004 is a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP that is actively recruiting participants, run by argenx. The registered enrollment target is 218 participants, above the 141-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT06920004, a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy and CIDP, is actively recruiting participants, sponsored by argenx.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 218 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emvigorate
Conditions Studied
Interventions
- OTHER IVIg-placebo
- BIOLOGICAL empasiprubart
- BIOLOGICAL IVIg
- OTHER empasiprubart-placebo
Study Locations (20)
Other
- Fakultni nemocnice Brno - Brno
- Astra Kliinik - Tallinn
- Tartu University Hospital - Tartu
- Charité - Universitätsmedizin Berlin - Berlin
- University General Hospital ''ATTIKON'' - General Hospital of West Attica H AGIA VARVARA - Chaïdári
- The Barzilai University Medical Center - Ashkelon
- Hadassah Medical Center- Ein Kerem - Jerusalem
- The Chaim Sheba Medical Center - Tel Litwinsky
- AUSL di Bologna - Ospedale Bellaria - Bologna
- Aomori Prefectural Central Hospital - Aomori
Florida
- Homestead Associates in Research Inc - Homestead
- Visionary Investigators Network - Miami
Michigan
- University of Michigan Hospital - Ann Arbor
- University of Michigan Hospital - Ann Arbor
Texas
- NeuroCarePlus - Houston
- National Neuromuscular Research Institute - Irving
Colorado
- Colorado Springs Neurological Associates - Colorado Springs
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Louisiana
- Paradigm Health System - Slidell
Maryland
- Erlanger Health System - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2025-08-22 |
| Est. Completion | 2030-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06920004
The ClinicalTrials.gov registry entry for NCT06920004 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 141-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (55% higher). The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 4 interventions - of which IVIg-placebo is the first listed.
NCT06920004 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT06920004 about?
NCT06920004 is a clinical study titled "A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP". The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Par...
What is the current status of trial NCT06920004?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2025-08-22. Estimated completion is 2030-09.
What conditions does trial NCT06920004 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT06920004?
The interventions under investigation include: IVIg-placebo (OTHER), empasiprubart (BIOLOGICAL), IVIg (BIOLOGICAL), empasiprubart-placebo (OTHER).
Who is sponsoring clinical trial NCT06920004?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06920004 being conducted?
This trial has 20 study locations across Colorado, District of Columbia, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
IVIG vs SCIG in CIDP
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.